These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 15547086

  • 1. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.
    Chang DM, Chu SJ, Chen HC, Kuo SY, Lai JH.
    Ann Rheum Dis; 2004 Dec; 63(12):1623-6. PubMed ID: 15547086
    [Abstract] [Full Text] [Related]

  • 2. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
    Chang DM, Lan JL, Lin HY, Luo SF.
    Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
    [Abstract] [Full Text] [Related]

  • 3. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE, GL601 Study Group.
    Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
    [Abstract] [Full Text] [Related]

  • 4. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.
    Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
    [Abstract] [Full Text] [Related]

  • 5. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
    Hartkamp A, Geenen R, Godaert GL, Bijl M, Bijlsma JW, Derksen RH.
    Ann Rheum Dis; 2010 Jun; 69(6):1144-7. PubMed ID: 19854713
    [Abstract] [Full Text] [Related]

  • 6. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
    Nordmark G, Bengtsson C, Larsson A, Karlsson FA, Sturfelt G, Rönnblom L.
    Autoimmunity; 2005 Nov; 38(7):531-40. PubMed ID: 16373258
    [Abstract] [Full Text] [Related]

  • 7. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Mease PJ, Ginzler EM, Gluck OS, Schiff M, Goldman A, Greenwald M, Cohen S, Egan R, Quarles BJ, Schwartz KE.
    J Rheumatol; 2005 Apr; 32(4):616-21. PubMed ID: 15801015
    [Abstract] [Full Text] [Related]

  • 8. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
    Barry NN, McGuire JL, van Vollenhoven RF.
    J Rheumatol; 1998 Dec; 25(12):2352-6. PubMed ID: 9858429
    [Abstract] [Full Text] [Related]

  • 9. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
    van Vollenhoven RF, Morabito LM, Engleman EG, McGuire JL.
    J Rheumatol; 1998 Feb; 25(2):285-9. PubMed ID: 9489820
    [Abstract] [Full Text] [Related]

  • 10. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, Canadian Network For Improved Outcomes in Systemic Lupus.
    Arthritis Rheum; 2008 Dec 15; 59(12):1796-804. PubMed ID: 19035431
    [Abstract] [Full Text] [Related]

  • 11. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE.
    J Rheumatol; 2008 Aug 15; 35(8):1567-75. PubMed ID: 18634158
    [Abstract] [Full Text] [Related]

  • 12. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
    Van Vollenhoven RF, McGuire JL.
    Ann Med Interne (Paris); 1996 Aug 15; 147(4):290-6. PubMed ID: 8952750
    [Abstract] [Full Text] [Related]

  • 13. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C, Wallace DJ, Shinada S, Kalunian KC, Forbess L, Braunstein GD, Weisman MH.
    Rheumatology (Oxford); 2008 Mar 15; 47(3):334-8. PubMed ID: 18238794
    [Abstract] [Full Text] [Related]

  • 14. Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus.
    Suzuki N, Suzuki T, Sakane T.
    Ann Med Interne (Paris); 1996 Mar 15; 147(4):248-52. PubMed ID: 8952743
    [Abstract] [Full Text] [Related]

  • 15. Effects of sex hormones on apoptosis in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
    Liu C, Zhou H, Qu R, Liu Z.
    Chin Med J (Engl); 2001 Mar 15; 114(3):291-3. PubMed ID: 11780316
    [Abstract] [Full Text] [Related]

  • 16. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS, Pereira FV, de Sá MF, Paulo LJ, Martins WP, Ferriani RA.
    Maturitas; 2009 Mar 20; 62(3):311-6. PubMed ID: 19193505
    [Abstract] [Full Text] [Related]

  • 17. Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus.
    Suárez A, López P, Mozo L, Gutiérrez C.
    Ann Rheum Dis; 2005 Nov 20; 64(11):1605-10. PubMed ID: 15800006
    [Abstract] [Full Text] [Related]

  • 18. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial.
    Hartkamp A, Geenen R, Godaert GL, Bootsma H, Kruize AA, Bijlsma JW, Derksen RH.
    Ann Rheum Dis; 2008 Jan 20; 67(1):91-7. PubMed ID: 17545193
    [Abstract] [Full Text] [Related]

  • 19. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Jan 20; 16(5):897-906. PubMed ID: 19436226
    [Abstract] [Full Text] [Related]

  • 20. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD.
    J Clin Psychopharmacol; 2006 Oct 20; 26(5):495-9. PubMed ID: 16974191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.